Quantumzyme Corp. (OTCQB: QTZM), a biotechnology company focused on enzyme engineering and green chemistry, announced details regarding the World Intellectual Property Organization (WIPO) publication of its international patent application titled “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen” (Publication No. WO 2025/093935 A1). Although published in May 2025, the company is highlighting it now to underscore its progress toward sustainable pharmaceutical manufacturing and its broader growth strategy.
This international patent joins a previously announced U.S. Patent Application (U.S. Patent Application Publication No. US 2025/0146029 A1), together providing broad protection for Quantumzyme’s proprietary enzyme engineering platform in both domestic and international markets. The patents cover a biocatalytic method for producing ibuprofen that reduces chemical waste, eliminates harsh reagents, and enhances manufacturing efficiency.
“The publication of our patents both in the USA and internationally mark an important milestone for Quantumzyme,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “It validates the strength of our enzyme engineering technology and enhances our position for global partnerships focused on greener, more efficient pharmaceutical manufacturing. It also allows us to advance into the optimization and pilot-testing phase, and engaging with potential partners interested in sustainable and scalable API production.”
The patented ibuprofen synthesis builds on Quantumzyme’s QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts. This technology underpins multiple enzyme systems for sustainable, high-efficiency production of active pharmaceutical ingredients (APIs) and specialty chemicals.
Quantumzyme intends to continue laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process, pursue discussions with global pharmaceutical and contract manufacturing organizations (CMOs) regarding licensing or joint-development frameworks, and file additional patent applications covering related enzymatic transformations and process improvements.
For more information, visit the company’s website at www.quantumzymecorp.com and its profile at www.otcmarkets.com/stock/QTZM.
